Abstract
Endometriosis (EM) is a chronic gynecological disorder affecting roughly 5-10% of women in their reproductive age, with symptom onset often occurring during adolescence but diagnosis frequently delayed for several years. Its pathogenesis is multifactorial, involving immunological, hormonal, genetic, and environmental factors. Increasing evidence suggests that immune dysregulation, particularly involving the complement system, a key effector of innate immunity and mediator of inflammatory responses, contributes to EM pathogenesis by sustaining chronic inflammation, angiogenesis, and lesion development. This review summarizes the available evidence on the involvement of complement components in EM pathogenesis and evaluates their potential use as biomarkers. A systematic literature search was performed in PubMed, Scopus, and Embase following PRISMA guidelines, including all eligible studies published up to July 2026. After full-text screening, 64 of 652 studies were selected and included in the final analysis. Overall, evidence supported a predominant involvement of the alternative complement pathway in EM, with complement component C3 emerging as the most extensively investigated molecule (35/64 studies). Evidence for the classical and lectin pathways was comparatively limited and heterogeneous. Moreover, several complement regulators emerged as differentially expressed in transcriptomic studies of endometriotic lesions. Overall, complement dysregulation appeared to be predominantly localized to the lesion microenvironment, while evidence of systemic complement activation remained limited. C3, C7, and FH emerged as the most consistently dysregulated molecules and appeared to be promising candidates for a complement-based biomarker panel for EM. Further validation in well-characterized and independent cohorts is required to determine their diagnostic value.
1 Introduction
Endometriosis (EM) is a chronic inflammatory condition affecting approximately 10% of women worldwide and is characterized by the presence of endometrial-like tissue outside the uterine cavity. Based on the anatomical location and depth of lesions, EM is classified broadly into three major subtypes: peritoneal, ovarian, and deep infiltrating EM (7, ).
). To date, no unified theory fully explains the pathogenesis of EM, and accumulating evidence on the role of immunological, hormonal, genetic, and environmental factors highlights the disease’s complexity and multifactorial nature. In contrast, a wide array of risk factors for EM development have been consistently identified, including early menarche, shorter menstrual cycles, nulliparity, a lower body mass index, and potentially environmental exposure to endocrine-disrupting molecules ( ). Researchers have demonstrated a significant heritable component ( ), leading to the identification of multiple genetic susceptibility loci, some of which are shared with other inflammatory conditions ( , ). Both inherited and acquired genetic and epigenetic alterations may contribute to disease development and progression, partly explaining lesion heterogeneity ( ). Finally, recent studies have investigated the effect of the microbiome on EM development, although the relationship between gut microbiota composition and EM remains controversial (Despite advances in the field, early clinical recognition of EM remains challenging beacuse of heterogeneous presentation and a lack of reliable non-invasive diagnostic tools (
). The severity of symptoms ranges from asymptomatic disease to severe pelvic pain, dysmenorrhea, and infertility, resulting in an interval between symptom onset and diagnosis of around seven years in adults and delays exceeding twelve years for adolescence-onset cases. Adolescents diagnosed with EM often experience an earlier onset of menstruation, longer menstrual cycles, more severe dysmenorrhea, and atypical symptoms compared with women diagnosed later in life ( ). The need for early detection has prompted extensive research into reliable biomarkers with adequate sensitivity and specificity ( ). Among potential biomarker candidates, immune-related molecules have attracted considerable attention due to the central role of inflammation in EM pathophysiology.In recent years, the fundamental role of immune dysregulation in endometriotic lesion development has been gradually unveiled, involving both innate and adaptive immunity, which may contribute to disease susceptibility and progression, immune escape, and maintenance of a chronic inflammatory microenvironment (
). One of the most prominent immune pathways involved in EM pathogenesis is the complement system ( ).1.1 The complement system
The complement system is a key part of innate immunity, and also serves as a functional bridge to adaptive immunity. It consists of more than 50 soluble and membrane-associated proteins that interact through a tightly regulated proteolytic cascade (Figure 1). Traditionally, it is involved in tissue homeostasis and host defense through the production of pro-inflammatory anaphylatoxins, opsonization, and target lysis ( ), although several non-canonical functions have recently been identified.
Figure 1
Complement activation may occur through three major pathways: the classical, the lectin, and the alternative pathways (
). Although triggered by distinct mechanisms, all three pathways converge at the level of C3, ultimately leading to its cleavage into the anaphylatoxin C3a and the opsonin C3b, which contributes to the formation of C5 convertases. Cleavage of C5 results in the anaphylatoxin C5a and C5b, which initiates the terminal pathway. Sequential association of C5b with C6, C7, C8, and multiple C9 molecules results in the formation of the Membrane Attack Complex (MAC, C5b-9), a pore-forming structure capable of inducing target cell lysis. Simultaneously, C3a and C5a act as inflammatory mediators and chemoattractants via binding to their receptors, C3aR and C5aR1/2.The classical pathway is generally initiated via recognition of antigen-antibody complexes by C1q, leading to the activation of the associated serine proteases C1r and C1s. Similarly, the lectin pathway is triggered by the recognition of pathogen-associated carbohydrate structures by pattern-recognition molecules such as mannose-binding lectin (MBL), ficolins, and collectins, which activate the MBL-associated serine proteases (MASPs). Activation of both pathways results in the generation of the C3 convertase (C4b2a) and drives progression of the cascade (
).In contrast, the alternative pathway is characterized by the “tick-over”, a low level of continuous activation due to spontaneous hydrolysis of C3 to C3(H2O). This process leads to the formation of the fluid-phase C3 convertase [C3(H2O)Bb] and the surface-bound C3 convertase (C3bBb) through the involvement of Factor B (FB) and Factor D (FD). The peculiarity of this pathway is an amplification loop, as generated C3b can continuously promote further convertase formation. The plasma protein Properdin (FP) is a stabilizer of alternative C3 convertases, and the subsequent formation of the C5 convertase promotes activation of the terminal complement pathway (
).Given its potent pro-inflammatory and cytolytic potential, complement activation must be tightly regulated to prevent host tissue damage. Many soluble and membrane-bound regulators act at different stages of the cascade (
, ). C1 inhibitor (C1INH, encoded by the SERPING1 gene) controls the initiation of the classical and lectin pathways by inhibiting C1r, C1s, and MASPs. At the level of C3 and C5 convertases, Factor I (FI), together with cofactors such as Factor H (FH), C4b-binding protein (C4BP), Membrane Cofactor Protein (MCP, also known as CD46), and Complement Receptor 1 (CR1, also known as CD35), contributes to C3b and C4b degradation and limits convertase activity. Additionally, FH, C4BP, MCP, and CR1, along with the Decay-Accelerating Factor (DAF, also known as CD55), accelerate convertase dissociation. Finally, MAC assembly can be inhibited by the membrane-bound regulator CD59 and the plasma proteins vitronectin (also called S protein) and clusterin (CLU). Binding of vitronectin to C5b-9 creates the soluble and non-lytic sC5b-9 (or soluble Terminal Complement Complex, sTCC).1.2 The complement system in endometriosis pathogenesis
Given the well-established involvement of complement dysregulation in several pathological conditions, including tumour growth, invasion, and metastasis (
, ), its contribution to the development and progression of EM appears biologically plausible, being supported by accumulating evidence ( , ). Moreover, the chronic inflammatory nature of EM provides a favorable context for complement activation, as tissue damage is a widely recognized trigger of the complement cascade and its downstream pro-inflammatory effects ( ). Both early and more recent studies have reported altered expression of complement components and regulators in endometriotic lesions compared with matched eutopic endometrium, suggesting a major complement imbalance ( ). The complement system has been implicated not only in sustaining chronic inflammation but also, potentially, in the progression of a subset of lesions toward EM-associated ovarian cancer ( , ).Interestingly, the complement system is closely interconnected with the coagulation pathway, and they reciprocally influence each other’s activity (
). This relationship has also been observed in EM, where enrichment of both pathways has been consistently reported ( , ). In particular, a positive correlation between the expression of complement components and Tissue Factor was detected in endometriotic lesions ( ). Together with increasing observations of a hypercoagulable state in EM patients ( , ), these findings suggest a cooperative role of complement and coagulation in EM pathogenesis.The contribution of individual complement pathways and components to EM pathogenesis remains unclear. Most studies have previously focused on the secretion, activation, and pathogenetic role of C3 beacuse of its central position in all three complement pathways, while only a limited number of more recent studies have attempted to characterize the function of other complement components in this disease.
2 Methods
2.1 Search methods and data sources
A systematic literature search was conducted to identify studies reporting complement component expression in EM. The search strategy was developed in accordance with the recommendations of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Supplementary Table 1.
). Three databases (PubMed, Scopus, and Embase) were systematically interrogated for relevant articles published up to July 31, 2026, with no restriction on publication date. The search terms included combinations of the keywords “complement” AND “endometriosis”, with results limited to studies published in English. The full search strategy is provided in the2.2 Selection of studies
Removal of duplicates and screening of records were performed using the Rayyan tool (
). Two independent reviewers (A.B. and C.A.) retrieved all articles based on titles and abstracts, followed by full-text assessment for eligibility. Relevant studies were included if they met all the following criteria: 1) published in English; 2) original peer-reviewed articles; and 3) studies investigating the RNA/DNA expression, protein abundance, or functional involvement of at least one complement component in EM. Eligible studies included investigations involving human samples, in vitro experiments using relevant cellular models, and transcriptomic analyses, provided that they specifically addressed complement components in the context of EM. Articles were excluded if they were: 1) published in languages other than English; 2) case reports or series; 3) reviews, systematic reviews, meta-analyses, book chapters, conference papers, or commentaries; 4) studies conducted exclusively in animal models without relevant human data; and 5) studies not investigating at least one complement component in EM. Discrepancies between reviewers were resolved by a third investigator (R.B.).All studies meeting the inclusion criteria were included in the present review.
2.3 Data extraction
The following data were extracted from each included study: the first author’s name, year of publication, reference, type of biological sample analyzed (i.e., serum, ectopic/eutopic tissue, peritoneal fluid, genomic DNA, or isolated cells), methods used for the assessment of complement components (e.g., ELISA, immunohistochemistry, proteomics, transcriptomic analyses), and sample size (EM patients vs control patients). In addition, information on the specific complement components investigated and their reported expression levels (i.e., increased or decreased expression/levels in EM compared with controls) was collected.
3 Results
3.1 Studies included for systematic review
The study selection process is illustrated in Figure 2. A total of 652 records were retrieved through database searching. Duplicates (n = 281) were removed via Rayyan, and the remaining 371 records were screened based on title and abstract. During screening, 243 records were excluded for the following reasons: not relevant to the topic (n = 155) and wrong publication type (n = 88). A total of 128 full-text articles were assessed for eligibility. Of these, 67 full-text articles were excluded for the following reasons: wrong publication type (n = 46), not relevant to the topic (n = 12), no full text available (n = 5), animal studies (n = 3), and non-English language (n = 1). Additional studies were identified through cross-reference checking and included in the review (n = 3). Ultimately, 64 studies were included in this systematic review. The included studies are reported in Table 1 and Supplementary Table 2.
Figure 2
Table 1
| Complement component (n studies) | Biological sample | Methodology | Study population | Outcome in EM | Reference |
|---|---|---|---|---|---|
| C1q (7) | ectopic vs eutopic tissue, healthy endometrium | RNA-seq, DB analysis | (114 ectopic vs 138 eutopic) EM vs 79 CTRL | ↑ | Golinska, 2025 ( | )
| ectopic vs eutopic tissue | IHC, qPCR | 6 EM vs 3 CTRL | ↑ | Agostinis, 2024 ( | )|
| ectopic vs eutopic tissue | RNA-seq, DB analysis, qPCR, WB | 36 EM vs 25 CTRL | ↑ | Yu, 2021 ( | )|
| ectopic vs eutopic tissue (P) | ncRNA-seq, DB analysis | 8 EM | ↑ | Wang, 2020 ( | )|
| PF | ELISA | 60 EM vs 20 CTRL | ↑ | Sikora, 2018 ( | )|
| ectopic vs eutopic tissue (P), cells | RNA-seq, qPCR | 4 EM vs 4 CTRL | ↑ | Rekker, 2017 ( | )|
| ectopic vs eutopic tissue | RNA-seq | 8 EM vs 8 CTRL | ↑ | Ahn, 2016 ( | )|
| C1r (3) | ectopic vs eutopic tissue | RNA-seq, DB analysis, qPCR, WB | 36 EM vs 25 CTRL | ↑ | Yu, 2021 ( | )
| ectopic vs eutopic tissue | RNA-seq, DB analysis | 26 EM vs 15 CTRL | ↑ | Heydari, 2020 ( | )|
| ectopic vs eutopic tissue | RNA-seq | 8 EM vs 8 CTRL | ↑ | Ahn, 2016 ( | )|
| C1s (6) | ectopic vs eutopic tissue | proteomics | 7 EM vs 8 CTRL | ↑ | Chen, 2024 ( | )
| ectopic vs eutopic tissue | RNA-seq, DB analysis, qPCR, WB | 36 EM vs 25 CTRL | ↑ | Yu, 2021 ( | )|
| ectopic vs eutopic tissue | RNA-seq, DB analysis | 26 EM vs 15 CTRL | ↑ | Heydari, 2020 ( | )|
| ectopic vs eutopic tissue (P) | ncRNA-seq, DB analysis | 8 EM | ↑ | Wang, 2020 ( | )|
| ectopic vs eutopic tissue | RNA-seq | 8 EM vs 8 CTRL | ↑ | Ahn, 2016 ( | )|
| ectopic vs eutopic tissue | microarray | 3 EM vs 3 CTRL | ↑ | Eyster, 2002 ( | )|
| C4 (19) | tubal epithelium | RNA-seq, qPCR | 4 EM vs 4 CTRL | ↑ | Qi, 2020 ( | )
| serum | immunoturbidimetry | 22 EM vs 30 CTRL | ↔ | Hussein, 2018 ( | )|
| serum | proteomics, WB | 15 EM vs 15 CTRL | ↑ | Hwang, 2014 ( | )|
| ectopic vs eutopic tissue | NanoString | 30 EM vs 32 CTRL | ↑ | Suryawanshi, 2014 ( | )|
| serum | proteomics | 547 EM vs 68 CTRL | ↑ | Dutta, 2015 (46) | |
| ectopic vs eutopic tissue | RNA-seq | 8 EM vs 8 CTRL | ↑ | Ahn, 2016 ( | )|
| ectopic vs eutopic tissue | RNA-seq | 11 EM vs 9 CTRL | ↑ | Vouk, 2011 (47) | |
| serum | proteomics | 8 OE and 8 PE EM vs 8 CTRL | ↓ | Wölfler, 2011 (48) | |
| serum | proteomics | 56 EM vs 20 CTRL (pool) | ↑ | Faserl, 2011 (49) | |
| serum, PF | ELISA | 80 EM vs 30 CTRL | ↑ | Kabut, 2007 (50) | |
| serum | immunoturbidimetry | 24 EM vs 10 CTRL | ↔ | Nomiyama, 1997 (51) | |
| serum | RID | 20 EM vs 30 CTRL | ↔ | Nip, 1995 (52) | |
| serum | RID | 71 EM vs 109 CTRL | ↔ | Taylor, 1991 (53) | |
| serum | RID | 20 EM vs 20 CTRL | ↔ | Meek, 1988 (54) | |
| PF, serum | RID (PF/serum ratio) | 25 EM vs 45 CTRL | ↔ | Dunselman, 1988 (55) | |
| eutopic endometrium | IF | 35 EM vs 15 CTRL | ↔ | Bartosik, 1987 (56) | |
| PF | RID | 45 EM vs 57 CTRL | ↑ | Badaway, 1984 (57) | |
| serum | RID | 10 EM vs 10 CTRL | ↔ | Matalliotakis, 1994 (58) | |
| serum | RID | 27 EM vs 26 CTRL infertile | ↔ | Steele, 1984 (59) | |
| C2 (5) | ectopic vs eutopic tissue, healthy endometrium | RNA-seq, DB analysis | (114 ectopic vs 138 eutopic) EM vs 79 CTRL | ↑ | Golinska, 2025 ( | )
| ectopic vs eutopic tissue (P) | ncRNA-seq, DB analysis | 8 EM | ↑ | Wang, 2020 ( | )|
| tubal epithelium | RNA-seq, qPCR | 4 EM vs 4 CTRL | ↑ | Qi, 2020 ( | )|
| peripheral blood (DNA) | SNP genotyping | 171 EM vs 2934 CTRL | SNP association | Sobalska-Kwapis, 2017 (60) | |
| ectopic vs eutopic tissue | RNA-seq | 8 EM vs 8 CTRL | ↑ | Ahn, 2016 ( | )|
| MBL (4) | ectopic vs eutopic tissue, serum | qPCR, IHC, ELISA | 38 EM vs 20 CTRL | ↔ | Toffoli, 2025 (61) |
| PF | ELISA | 60 EM vs 20 CTRL | ↑ | Sikora, 2018 ( | )|
| serum | ELISA | 32 EM vs 32 CTRL | ↔ | Ozerkan, 2010 (62) | |
| PF | ELISA | 25 EM vs 11 CTRL | ↔ | Kavoussi, 2006 (63) | |
| MASP1 | ectopic vs eutopic tissue | NanoString | 30 EM vs 32 CTRL | ↓ | Suryawanshi, 2014 ( | )
| MASP2 | ectopic vs eutopic tissue, serum | qPCR, IHC, ELISA | 38 EM vs 20 CTRL | ↔ | Toffoli, 2025 (61) |
| MASP3 | serum, PF | ELISA | 32 EM vs 26 CTRL | ↔ | Eskin Tanriverdi, 2025 (64) |
| C3 (35) | ectopic vs eutopic tissue, healthy endometrium | RNA-seq, DB analysis | (114 ectopic vs 138 eutopic) EM vs 79 CTRL | ↑ | Golinska, 2025 ( | )
| endometrioma vs ovarian tissue | scRNA-seq, IF | 3 EM vs 3 CTRL | ↑ | Chen, 2025 (65) | |
| plasma | ELISA | 40 EM vs 40 CTRL | ↑ | Sanjay, 2024 (66) | |
| ectopic vs eutopic tissue | proteomics | 7 EM vs 8 CTRL | ↑ | Chen, 2024 ( | )|
| ectopic vs eutopic tissue | scRNA-seq | 17 EM vs 4 CTRL | ↑ | Fonseca, 2023 (67) | |
| ectopic vs eutopic tissue | RNA-seq, DB analysis | 50 EM vs 49 CTRL | ↑ | Gan, 2022 (68) | |
| ectopic vs eutopic tissue; primary cells; cell lines | IHC, qPCR, ELISA | 5 EM vs 5 CTRL | ↑ | Agostinis, 2021 (69) | |
| ectopic vs eutopic tissue | RNA-seq, DB analysis, qPCR, WB | 36 EM vs 25 CTRL | ↑ | Yu, 2021 ( | )|
| ectopic vs eutopic tissue (P) | ncRNA-seq, DB analysis | 8 EM | ↑ | Wang, 2020 ( | )|
| ectopic vs eutopic tissue | RNA-seq, DB analysis | 26 EM vs 15 CTRL | ↑ | Heydari, 2020 ( | )|
| serum | ELISA | 44 EM vs 44 CTRL | ↑ | Hasan, 2019 (70) | |
| serum | immunoturbidimetry | 22 EM vs 30 CTRL | ↔ | Hussein, 2018 ( | )|
| ectopic vs eutopic tissue (P), cells | RNA-seq, qPCR | 4 EM vs 4 CTRL | ↑ | Rekker, 2017 ( | )|
| ectopic vs eutopic tissue | RNA-seq | 8 EM vs 8 CTRL | ↑ | Ahn, 2016 ( | )|
| serum | Luminex assay | 20 EM vs 3 CTRL | ↑ | Signorile, 2016 (71) | |
| serum | proteomics | 547 EM vs 68 CTRL | ↓ | Dutta, 2015 (46) | |
| ectopic vs eutopic tissue | NanoString | 30 EM vs 32 CTRL | ↑ | Suryawanshi, 2014 ( | )|
| cells, ectopic vs eutopic tissue (P) | ELISA, IHC | 10 EM vs 3 CTRL | ↑ | Kobayashi, 2012 (72) | |
| ectopic vs eutopic tissue | RNA-seq | 11 EM vs 9 CTRL | ↑ | Vouk, 2011 (47) | |
| peripheral blood (DNA) | SNP genotyping | 214 EM vs 147 CTRL | SNP association | Ruiz, 2011 (73) | |
| serum | proteomics | 56 EM vs 20 CTRL (pool) | ↓ | Faserl, 2011 (49) | |
| ectopic vs eutopic tissue (P) | ISH, IHC, WB | 12 EM | ↑ | Tao, 1997 (74) | |
| serum | immunoturbidimetry | 24 EM vs 10 CTRL | ↔ | Nomiyama, 1997 (51) | |
| ectopic vs eutopic tissue | ISH, IHC | 2 EM vs 2 CTRL | ↔ | Sayegh, 1996 (75) | |
| serum | RID | 20 EM vs 30 CTRL | ↔ | Nip, 1995 (52) | |
| eutopic endometrium (cell cultures) | IHC, RIA | 2 EM vs 9 CTRL | ↑ | Bischof, 1994 (76) | |
| serum | RID | 71 EM vs 109 CTRL | ↔ | Taylor, 1991 (53) | |
| eutopic endometrium | pulse-chase, IP | 16 EM vs 7 CTRL (infert) | ↑ | Isaacson, 1990 (77) | |
| ectopic endometrium | pulse-chase, IP | 17 EM vs 8 CTRL | ↑ | Isaacson, 1989 (78) | |
| serum | RID | 20 EM vs 20 CTRL | ↓ | Meek, 1988 (54) | |
| PF, serum | RID (PF/serum ratio) | 25 EM vs 45 CTRL | ↔ | Dunselman, 1988 (55) | |
| eutopic endometrium | IF | 35 EM vs 15 CTRL | ↔ | Bartosik, 1987 (56) | |
| serum | RID | 10 EM vs 10 CTRL | ↔ | Matalliotakis, 1994 (58) | |
| PF | RID | 45 EM vs 57 CTRL | ↑ | Badaway, 1984 (57) | |
| serum | RID | 27 EM vs 26 CTRL | ↔ | Steele, 1984 (59) | |
| C3a (2) | PF | ELISA | 16 EM vs 8 CTRL | ↑ | Agostinis, 2021 (69) |
| serum | ELISA | 71 EM vs 77 CTRL | ↔ | Karadadas, 2020 (79) | |
| C3c (1) | serum, PF | ELISA | 80 EM vs 30 CTRL | ↑ | Kabut, 2007 (50) |
| C3d (2) | ectopic vs eutopic tissue (P), healthy endometrium | IF | 6 EM vs 6 CTRL | ↑ | D’Cruz, 1992 (80) |
| ectopic vs eutopic tissue (P), healthy endometrium | IHC | 30 EM vs 10 CTRL | present | Nomiyama, 1997 (51) | |
| C3a-des-Arg (1) | plasma | ELISA | 109 EM vs 51 CTRL | ↔ | Fassbender, 2009 (81) |
| iC3b (1) | serum, PF | ELISA | 80 EM vs 30 CTRL | ↓ | Kabut, 2007 (50) |
| FB (6) | eutopic endometrium | proteomics | 4 EM vs 4 CTRL | ↑ | Yao, 2021 (82) |
| ectopic vs eutopic tissue | RNA-seq | 4 EM vs 4 CTRL | ↑ | Predeus, 2018 (83) | |
| ectopic vs eutopic tissue | RNA-seq | 8 EM vs 8 CTRL | ↑ | Ahn, 2016 ( | )|
| serum | proteomics | 547 EM vs 68 CTRL | ↓ | Dutta, 2015 (46) | |
| ectopic vs eutopic tissue | NanoString | 30 EM vs 32 CTRL | ↑ | Suryawanshi, 2014 ( | )|
| serum | proteomics | 56 EM vs 20 CTRL (pool) | ↑ | Faserl, 2011 (49) | |
| FD (7) | endometrioma vs ovarian tissue | scRNA-seq | 3 EM vs 3 CTRL | ↑ | Chen, 2025 (65) |
| serum, PF | ELISA | 32 EM vs 26 CTRL | ↑ | Eskin Tanriverdi, 2025 (64) | |
| ectopic vs eutopic tissue | RNA-seq, DB analysis | 74 EM vs 74 CTRL | ↑ | Liang, 2024 (84) | |
| ectopic vs eutopic tissue | RNA-seq, DB analysis | 37 EM vs 22 CTRL | ↓ | Huang, 2022 (85) | |
| ectopic vs eutopic tissue (P) | RNA-seq, DB analysis | 15 EM vs 19 CTRL | ↑ | Xie, 2022 ( | )|
| ectopic vs eutopic tissue | RNA-seq | 6 EM vs 3 CTRL | ↑ | Rekker, 2017 ( | )|
| ectopic vs eutopic tissue | NanoString | 30 EM vs 32 CTRL | ↑ | Suryawanshi, 2014 ( | )|
| FP (3) | serum, PF | ELISA | 32 EM vs 26 CTRL | ↔ | Eskin Tanriverdi, 2025 (64) |
| ectopic vs eutopic tissue (P) | ncRNA-seq, DB analysis | 8 EM | ↑ | Wang, 2020 ( | )|
| ectopic vs eutopic tissue | RNA-seq | 8 EM vs 8 CTRL | ↑ | Ahn, 2016 ( | )|
| C5 (2) | ectopic vs eutopic tissue | RNA-seq | 8 EM vs 8 CTRL | ↑ | Ahn, 2016 ( | )
| ectopic vs eutopic tissue (P) | qPCR | 6 EM | ↑ | Aslan, 2014 (86) | |
| C5a (2) | serum | ELISA | 71 EM vs 77 CTRL | ↔ | Karadadas, 2020 (79) |
| serum | ELISA | 95 EM vs 50 CTRL | ↑ | Rahal, 2023 (87) | |
| C6 (3) | ectopic vs eutopic tissue, healthy endometrium | RNA-seq, DB analysis | (114 ectopic vs 138 eutopic) EM vs 79 CTRL | ↑ | Golinska, 2025 ( | )
| serum | ELISA | 71 EM vs 77 CTRL | ↔ | Karadadas, 2020 (79) | |
| ectopic vs eutopic tissue | RNA-seq | 8 EM vs 8 CTRL | ↑ | Ahn, 2016 ( | )|
| C7 (13) | ectopic vs eutopic tissue, healthy endometrium | RNA-seq, DB analysis | (114 ectopic vs 138 eutopic) EM vs 79 CTRL | ↑ | Golinska, 2025 ( | )
| ectopic vs eutopic tissue | proteomics | 7 EM vs 8 CTRL | ↑ | Chen, 2024 ( | )|
| ectopic vs eutopic tissue | scRNA-seq | 17 EM vs 4 CTRL | ↑ | Fonseca, 2023 (67) | |
| ectopic vs eutopic tissue | RNA-seq, DB analysis | 50 EM vs 49 CTRL | ↑ | Gan, 2022 (68) | |
| ectopic vs eutopic tissue | RNA-seq, DB analysis | 90 EM vs 38 CTRL | ↑ | Bae, 2022 (88) | |
| eutopic endometrium | proteomics | 4 EM vs 4 CTRL | ↑ | Yao, 2021 (82) | |
| ectopic vs eutopic tissue (P) | ncRNA-seq, DB analysis | 8 EM | ↑ | Wang, 2020 ( | )|
| ectopic vs eutopic tissue | RNA-seq, DB analysis | 26 EM vs 15 CTRL | ↑ | Heydari, 2020 ( | )|
| ectopic vs eutopic tissue (P) | RNA-seq | 10 EM vs 9 CTRL | ↑ | Predeus, 2018 (83) | |
| ectopic vs eutopic tissue (P), cells | RNA-seq, qPCR | 4 EM vs 4 CTRL | ↑ | Rekker, 2017 ( | )|
| ectopic vs eutopic tissue | RNA-seq | 8 EM vs 8 CTRL | ↑ | Ahn, 2016 ( | )|
| ectopic vs eutopic tissue | NanoString, IHC | 30 EM vs 32 CTRL | ↑ | Suryawanshi, 2014 ( | )|
| ectopic vs eutopic tissue; peritoneum | microarray, IHC | 18 EM vs 17 CTRL (endometrium) vs 22 CTRL (peritoneum) | ↑ | Sohler, 2013 (89) | |
| C8 (2) | ectopic vs eutopic tissue | RNA-seq | 8 EM vs 8 CTRL | ↑ | Ahn, 2016 ( | )
| ectopic vs eutopic tissue (P) | qPCR | 6 EM | ↑ | Aslan, 2014 (86) | |
| C9 (2) | plasma | proteomics | 464 EM vs 153 CTRL (vs 132 symptomatic CTRL) | ↑ | Schoeman, 2025 (90) |
| serum | proteomics | 547 EM vs 79 CTRL | ↑ | Dutta, 2015 (46) | |
| sC5b9 (3) | serum, PF | ELISA | 80 EM vs 30 CTRL | ↑ | Kabut, 2007 (50) |
| PF | ELISA | 18 EM vs 14 CTRL | ↔ | Riley, 2007 (91) | |
| ectopic vs eutopic tissue (P), healthy endometrium | IF | 6 EM vs 6 CTRL | ↑ | D’Cruz, 1992 (80) | |
| C1INH (5) | ectopic vs eutopic tissue | RNA-seq, DB analysis | 37 EM vs 22 CTRL | ↓ | Huang, 2022 (85) |
| ectopic vs eutopic tissue | RNA-seq, DB analysis, qPCR, WB | 36 EM vs 25 CTRL | ↑ | Yu, 2021 ( | )|
| ectopic vs eutopic tissue | RNA-seq, DB analysis | 26 EM vs 15 CTRL | ↑ | Heydari, 2020 ( | )|
| PF | ELISA | 60 EM vs 20 CTRL | ↑ | Sikora, 2018 ( | )|
| ectopic vs eutopic tissue (P), cells | RNA-seq, qPCR | 4 EM vs 4 CTRL | ↑ | Rekker, 2017 ( | )|
| FH (14) | serum, PF | ELISA | 32 EM vs 26 CTRL | ↑ | Eskin Tanriverdi, 2025 (64) |
| ectopic vs eutopic tissue | scRNA-seq | 17 EM vs 4 CTRL | ↑ | Fonseca, 2023 (67) | |
| ectopic vs eutopic tissue (P) | RNA-seq, DB analysis | 15 EM vs 19 CTRL | ↑ | Xie, 2022 ( | )|
| ectopic vs eutopic tissue | RNA-seq, DB analysis | 90 EM vs 38 CTRL | ↑ | Bae, 2022 (88) | |
| ectopic vs eutopic tissue | RNA-seq, DB analysis | 50 EM vs 49 CTRL | ↑ | Gan, 2022 (68) | |
| ectopic vs eutopic tissue | RNA-seq, DB analysis | 37 EM vs 22 CTRL | ↑ | Huang, 2022 (85) | |
| ectopic vs eutopic tissue | RNA-seq, DB analysis | 26 EM vs 15 CTRL | ↑ | Heydari, 2020 ( | )|
| ectopic vs eutopic tissue (P) | ncRNA-seq, DB analysis | 8 EM | ↑ | Wang, 2020 ( | )|
| ectopic vs eutopic tissue (P), cells | RNA-seq, qPCR | 4 EM vs 4 CTRL | ↑ | Rekker, 2017 ( | )|
| ectopic vs eutopic tissue | RNA-seq | 8 EM vs 8 CTRL | ↑ | Ahn, 2016 ( | )|
| serum | proteomics | 547 EM vs 68 CTRL | ↑ | Dutta, 2015 (46) | |
| ectopic vs eutopic tissue | NanoString | 30 EM vs 32 CTRL | ↑ | Suryawanshi, 2014 ( | )|
| follicular fluid | proteomics | (4 infert vs 4 fert) EM vs 9 CTRL | ↑ (fert EM) | Lo Turco, 2013 (92) | |
| ectopic vs eutopic tissue | RNA-seq | 11 EM vs 9 CTRL | ↑ | Vouk, 2011 (47) | |
| FI (2) | ectopic vs eutopic tissue | RNA-seq | 8 EM vs 8 CTRL | ↑ | Ahn, 2016 ( | )
| follicular fluid | proteomics | (4 infert vs 4 fert) EM vs 9 CTRL | ↑ (infert EM) | Lo Turco, 2013 (92) | |
| C4BP (4) | ectopic vs eutopic tissue | RNA-seq, DB analysis | 37 EM vs 22 CTRL | ↓ | Huang, 2022 (85) |
| ectopic vs eutopic tissue (P), cells | RNA-seq, qPCR | 4 EM vs 4 CTRL | ↑ | Rekker, 2017 ( | )|
| ectopic vs eutopic tissue | RNA-seq | 8 EM vs 8 CTRL | ↓ | Ahn, 2016 ( | )|
| ectopic vs eutopic tissue | NanoString | 30 EM vs 32 CTRL | ↓ | Suryawanshi, 2014 ( | )|
| CD46/MCP (2) | eutopic endometrium | IHC | 47 EM vs 42 CTRL | ↔ | Palomino, 2018 (93) |
| PF | ELISA | 9 EM vs 23 CTRL | ↑ | McLaughlin, 1996 (94) | |
| DAF/CD55 (4) | ectopic vs eutopic tissue | RNA-seq, DB analysis | 37 EM vs 22 CTRL | ↓ | Huang, 2022 (85) |
| ectopic vs eutopic tissue | IHC, IF, WB | 47 EM vs 42 CTRL | ↓ | Palomino, 2018 (93) | |
| ectopic vs eutopic tissue (P), cells | RNA-seq, qPCR | 4 EM vs 4 CTRL | ↑ | Rekker, 2017 ( | )|
| ectopic vs eutopic tissue (P) | RNA-seq, IHC | 30 EM vs 32 CTRL | ↑ | Suryawanshi, 2014 ( | )|
| CD59 (1) | eutopic endometrium | IHC | 47 EM vs 42 CTRL | ↔ | Palomino, 2018 (93) |
| Clusterin (4) | ectopic vs eutopic tissue | proteomics | 7 EM vs 8 CTRL | ↑ | Chen, 2024 ( | )
| ectopic vs eutopic tissue (P) | RNA-seq, DB analysis | 15 EM vs 19 CTRL | ↑ | Xie, 2022 ( | )|
| ectopic vs eutopic tissue (P), cells | RNA-seq, qPCR | 4 EM vs 4 CTRL | ↑ | Rekker, 2017 ( | )|
| serum | proteomics | 547 EM vs 68 CTRL | ↑ | Dutta, 2015 (46) | |
| Vitronectin (2) | follicular fluid | proteomics | (4 infert vs 4 fert) EM vs 9 CTRL | ↑ (infert EM) | Lo Turco, 2013 (92) |
| serum | proteomics | 8 OE and 8 PE EM vs 8 CTRL | ↑ | Wölfler, 2011 (48) |
Summary of the studies investigating complement components in endometriosis.
CTRL, control; DB, database; IF, immunofluorescence; IHC, immunohistochemistry; IP, immunoprecipitation; ncRNA-seq, non-coding RNA-sequencing; OE, ovarian endometriosis; P, same patient; PE, peritoneal endometriosis; PF, peritoneal fluid; qPCR, quantitative PCR; RIA, radioimmunoassay; RID, radial immunodiffusion; RNA-seq, RNA-sequencing; scRNA-seq, single-cell RNA-sequencing; SNP, single-nucleotide polymorphism; WB, Western blot. ↑ , increased expression/levels; ↓ , decreased expression/levels; ↔ , no significant changes.
The complement components identified across the included studies were further categorized according to their role within the complement cascade.
3.2 Classical and lectin pathway
3.2.1 C4
C4 was frequently investigated alongside C3 due to their common use as diagnostic and prognostic biomarkers in autoimmune diseases. Overall, 19 studies evaluated C4 levels in EM, including 13 studies assessing serum levels (46, 48–55, 58, 59) and three studies investigating peritoneal fluid (PF) concentrations (50, 55, 57). The findings regarding serum C4 levels were heterogeneous, with four studies reporting increased levels ( , 46, 49, 50), eight indicating no significant differences ( , 51–55, 58, 59), and one reporting decreased levels in EM patients compared with controls (48). Studies evaluating PFs also reported conflicting results. In contrast, concordant findings were observed in transcriptomic studies, showing higher C4 expression in ectopic tissues than in matched eutopic tissues ( , , , 47).
, ,3.2.2 Other components (C1-complex, MBL, MASP1, MASP2, C2)
Seven studies investigated the expression of C1q or its encoding genes (C1QA, C1QB, and C1QC) in EM. Higher C1q levels were reported in the PFs from women with EM compared with controls (
). C1q was found to localize within the vascular compartment of ectopic lesions, showing increased expression in EM ( ). Furthermore, five transcriptomic studies consistently demonstrated upregulation of C1q genes in ectopic tissues compared with eutopic endometrium ( , , , , ).C1s and C1r also emerged as differentially expressed in EM. Particularly, C1S was evaluated in six studies and was found to be increased in four transcriptomic analyses comparing ectopic and eutopic tissues (
, , , , ). Two of these studies also reported increased C1R expression ( , ). Similarly, a proteomic study on serum samples demonstrated higher levels of C1s in women with EM ( ).Five studies investigated C2 in EM, with transcriptomic analysis reporting increased C2 expression in ectopic lesions compared with eutopic endometrium (60).
, , , ). In addition, one genetic study found a potential association between C2 variants and EM susceptibility (Findings regarding MBL were inconsistent across studies. A study reported increased MBL levels in PFs from EM patients (61–63). More recently, a higher incidence of MBL-deficient patients was observed in women with non-severe EM, whereas increased circulating MBL levels were observed in patients with severe disease (61).
), whereas additional studies did not observe significant differences in EM women, neither in PFs nor in serum samples (Data on MASPs were limited. One RNA-Seq study identified the MASP1 gene as downregulated in ectopic tissues compared with healthy controls (61). No significant differences in serum and PF MASP-3 levels were reported (64).
), whereas immunohistochemical analysis showed abundant MASP-2 expression in endometriotic lesions (3.3 Alternative pathway
3.3.1 C3
For the purpose of data presentation, C3 was included in the alternative pathway section, although it represents the central convergence point of all three complement pathways and therefore also contributes to the common terminal pathway. A total of 35 studies investigated C3 in the context of EM. Overall, findings consistently demonstrated increased C3 expression in endometriotic lesions. Higher C3 protein levels in ectopic tissue were reported across several studies evaluating endometriotic lesion samples (69, 74), although a few were inconclusive (56, 75). More recent transcriptomic analyses further confirmed these findings through RNA-seq ( , , , , , , , 47, 68), including two single-cell RNA-seq studies reporting upregulation of C3 gene expression in ectopic tissues (65, 67). Five studies specifically assessed C3 synthesis by endometrial or endometriotic cells and observed C3 increase under pathological conditions (69, 72, 76–78). Similarly, two of three studies detected elevated C3 levels in the PFs from women with EM compared with controls (55, 57, 69). Evidence on serum C3 levels was more heterogeneous. Three studies documented elevated circulating C3 levels in EM patients (66, 70, 71). Conversely, nine studies reported either lower levels or no significant differences between patients and controls ( , 46, 49, 51–54, 58, 59). Genetic evidence was limited, with one study revealing an association between EM susceptibility and C3 gene variants (73).
, ,Studies analyzing C3 activation fragments also yielded inconsistent results: higher C3a in PFs (69) and C3c in sera (50) were reported, while other studies found no differences in plasma C3a-des-Arg and C3a (79, 81). C3d presence was also investigated with inconclusive findings (51, 80). iC3b was reduced in serum and PF in EM patients (50).
3.3.2 Other components (FB, FD, FP)
FB and FD were investigated mainly through omics approaches. Evidence regarding FB was somewhat heterogeneous, including proteomic analysis of sera (46, 49) and eutopic endometrium (82), as well as transcriptomic studies of ectopic lesions ( , , 83). While one serum proteomic study reported reduced circulating FB levels, transcriptomic studies consistently demonstrated FB increase in ectopic lesions. Similarly, FD was identified as higher in five transcriptomic studies comparing ectopic and eutopic tissues ( , , , 65, 84), with only one study showing the opposite trend (85). Increased FD levels were also detected in sera and PFs of EM patients (64).
Higher FP expression was observed in two independent transcriptomic analyses of ectopic lesions (64).
, ), while no significant differences in circulating or peritoneal levels were observed in a recent study (3.4 Terminal pathway
3.4.1 C7
The complement component C7 was investigated in 13 studies (67, 68, 82, 83, 88, 89), most of which evaluated transcriptomic differences between ectopic and eutopic endometrial tissues. Across all studies, C7 was consistently higher in ectopic lesions compared with eutopic endometrium, including matched samples from the same patients.
, , , – , ,3.4.2 Other components (C5, C6, C8, C9, sC5b9)
Studies evaluating C5 in the sera of EM patients have primarily focused on its activation fragment, C5a. Two studies measured circulating C5a levels in women with EM and reported conflicting findings, with one study reporting significantly higher levels in EM (79) and the other detecting no significant differences (87). At the tissue level, two transcriptomic studies demonstrated higher C5 expression in endometriotic lesions than in healthy endometrium ( , 86).
Transcriptomic studies further supported the involvement of terminal pathway components in EM. In addition, RNA-seq analysis identified an increase of terminal pathway genes, including C5, C6, C7, and C8, in EM lesions (
, ).Proteomic analysis identified C9 as a differentially expressed protein in the sera of women with EM (46, 90). Circulating sC5b-9 levels showed no statistically significant differences between patients and controls (91), whereas another study reported higher sC5b-9 concentrations in both sera and PFs of EM patients (50). Moreover, immunofluorescence analysis demonstrated higher sC5b-9 deposition in endometriotic lesions than in healthy endometrial biopsies (80).
3.5 Complement regulators
3.5.1 FH
FH emerged as one of the most frequently reported complement regulators in EM. Ten transcriptomic studies have serendipitously identified FH among the genes upregulated in ectopic lesions compared to eutopic endometrium (47, 67, 68, 85, 88). In addition, proteomic analysis of serum samples reported higher FH levels in EM patients relative to controls (46). These observations were further supported by an ELISA-based study demonstrating significantly elevated FH concentrations in the sera of patients with EM (64). FH was also investigated in the context of EM-associated infertility, where proteomic analysis of follicular fluids from EM patients highlighted the presence of FH in women with EM who achieved pregnancy (92).
, , , , , ,3.5.2 Other regulators (C1INH, C4BP, CLU, FI, CD55, CD46)
Several complement regulators emerged as differentially expressed in transcriptomic studies of endometriotic lesions. Among these, C1INH was consistently reported as higher, with all but one study demonstrating increased expression in ectopic tissues (85). One study showed increased C1INH levels in the PFs of EM women ( ). Similarly, one transcriptomic study showed increased FI expression ( ); in addition, FI was found to be specifically higher in the follicular fluids of infertile EM patients (92). In contrast, C4BP expression was reduced in three of the four studies evaluating this regulator ( , , , 85). Evidence regarding membrane-bound complement regulators was more heterogeneous. CD55 levels were investigated in four studies with contrasting results ( , , 85, 93). Additionally, CD46 expression in eutopic endometrium did not differ significantly between women with and without EM (93), while increased levels of soluble CD46 were detected in the PFs of women with EM (94). CD59 expression did not differ significantly between eutopic endometrium from women with EM and healthy controls (93). CLU was identified as upregulated in two RNA-seq studies in endometriotic lesions ( , ) and in two proteomic studies in serum samples from EM patients ( , 46). Proteomic studies revealed increased VTN levels in follicular fluids and sera from EM patients (48, 92).
, , ,4 Discussion
When evaluating the complement system in EM, it is important to consider both the cascade’s complexity and the extensive interplay among its components. To facilitate interpretation of the available evidence, this systematic review first examined the role of individual complement components as potential biomarkers of EM, before integrating the findings into a broader overview of complement involvement in EM pathogenesis. First, it should be recognized that increased expression of complement components does not necessarily indicate activation of the complement cascade, particularly given the limited evidence for the generation of complement activation products in EM. Moreover, EM does not appear to be characterized by a uniform systemic activation, but rather by a predominantly local and microenvironment-specific complement dysregulation, as the most consistent alterations appear to occur at the lesion level.
Notably, first evidence linking the complement system and EM dates back to the 1980s (57, 59, 95). One of the most striking findings emerging from this review is that complement components were frequently identified as differentially expressed between healthy and pathological samples through unbiased transcriptomic or proteomic approaches rather than studies specifically designed to investigate complement biology, suggesting that its involvement is a recurrent feature across different experimental settings. Most studies relied exclusively on transcriptomic approaches; however, for some components transcriptomic findings were also corroborated at the tissue protein level. This confirmation was obtained for C1q, C1r, C1s, C3, C7, FB, and CLU, either within the same study using IHC, IF, or WB, or in independent proteomic studies. The main discrepancies between experimental approaches concerned circulating complement levels, particularly for C3 and C4, which were variable across studies depending on the assay used (e.g., proteomics, immunodiffusion/immunoturbidimetry, ELISA) and often did not mirror the consistent upregulation observed locally in endometriotic lesions. This is consistent with a predominantly local dysregulation of the complement system in EM, which may not be reflected in the circulation.
At the same time, considerable heterogeneity was observed among studies. Numerous studies utilizing similar technologies and biological samples have yielded different, and occasionally conflicting, results. This variability in findings may be partly attributed to a lack of patient stratification by lesion subtype, disease stage, and hormonal treatment status. Indeed, recent evidence indicates that ovarian, deep infiltrating, and peritoneal endometriotic lesions exhibit a distinct transcriptomic, epigenetic, and immunologic microenvironment (96), which may influence gene and protein expression profiles across studies.
,The analysis of the study cohorts included in this systematic review further highlights these limitations, revealing substantial clinical heterogeneity and incomplete patient characterization (Supplementary Table 2). Only 30/64 studies reported the histological subtype of EM lesions. When reported, ovarian EM was the predominant histological subtype, whereas peritoneal and deep infiltrating EM were less frequently included. Similarly, although disease stage was described in 38/64 studies, most cohorts included patients across a broad spectrum of disease severity (stages I-IV), while others focused exclusively on advanced stages (III-IV), limiting comparability across studies. Furthermore, fertility status was specified in 35 manuscripts, with several studies enrolling mixed populations of fertile and infertile patients. Hormonal treatment exposure was defined only in 26 studies, often including both treated and untreated patients. These differences in patient selection likely contributed to the heterogeneity observed across studies and may have influenced the reported biomarker results.
4.1 Classical and lectin pathways
Evidence collected in this review does not support a major involvement of the classical and lectin pathways in EM pathogenesis. First, research investigating circulating C4 levels in EM patients has yielded inconsistent results, despite transcriptomic studies generally supporting local upregulation of C4 within endometriotic lesions. Only a limited number of RNA-seq studies (3/19) identified C4 among the differentially expressed genes associated with EM. Furthermore, Agostinis et al. reported only weak C4d staining in ovarian endometriotic lesions (
), leading to exclude the hypothesis of massive complement activation via the classical and lectin pathways.Among the classical pathway components, C1q appears to play a more relevant role in EM due to its well-known complement-independent functions. Beyond its canonical role in the complement cascade, C1q contributes to wound healing and angiogenesis by promoting endothelial cell proliferation, migration, and neovessel sprouting, as previously demonstrated in physiological pregnancy, ischemia, and tumour microenvironment (97–100). Similar mechanisms may support angiogenesis in EM. In line with this hypothesis, C1q was found to localize around lesion-associated vessels, likely upon secretion by resident macrophages, and to promote angiogenesis in the lesion microenvironment through its interaction with endometriotic endothelial cells ( ).
The role of MBL in EM remains unclear, with available evidence arguing against a major contribution from local MBL-mediated complement activation. Studies evaluating MBL levels in sera and PFs have yielded conflicting results; MBL expression was not detected in ectopic tissues, and only weak staining was observed in the eutopic endometrium (61). Interestingly, higher MBL circulating levels were reported in women with severe EM (61), likely reflecting the chronic inflammatory state associated with EM, as MBL is an acute-phase protein produced by the liver. Nevertheless, MBL may contribute to EM pathogenesis indirectly through its role in host-microbiota interplay. Endometrial microbial profiling revealed significant dysbiosis in EM patients, which was linked to MBL deficiency (61). Given the key role of the lectin pathway in pathogen recognition and elimination, decreased MBL levels impair regulation of microbiota composition in the reproductive tract. The consequent lack of microbial control may facilitate pathogen migration from the lower to the upper reproductive tract, thereby exacerbating inflammation and potentially supporting endometrial cell dissemination, as proposed for Fusobacterium infection (101).
It is noteworthy that only three studies have investigated the relationship between the complement system and genetic susceptibility to EM, one of which identified C2 variants associated with EM risk (60). Since other studies have not suggested a predominant role for activation of the classical or lectin pathway in EM, this observation warrants further investigation to determine whether C2 variants, in concert with other key genes, may be implicated in EM pathogenesis. However, the contribution of ficolin- or collectin-mediated lectin pathway activation has not yet been explored and may provide further insights into the role of this pathway in EM.
4.2 Alternative pathway
Among the three complement pathways, the alternative pathway appears most strongly implicated in EM pathogenesis. Notably, evidence supporting C3 involvement dates back to the 1980s, when C3 was first detected in the eutopic endometrium of patients and shown to be expressed by both epithelial and stromal cells (76, 95). Early studies using techniques such as radial immunoassay, immunoprecipitation/Western blot, and immunohistochemistry consistently detected increased C3 levels in blood, PF, and endometriotic lesions. Further evidence demonstrated significantly increased C3 synthesis and secretion by epithelial cells of ectopic lesions compared with matched eutopic endometrium (74, 78). Advances in transcriptomic technologies have consistently confirmed C3 upregulation in ectopic tissues ( , , , , , , , 47, 67, 68). Moreover, several findings suggest that C3 activation is dysregulated in EM. Specifically, lower levels of the inactive fragment iC3b in both PFs and sera of patients compared with controls, along with increased concentrations of C3c, may reflect an imbalance in C3b inactivation in EM (50). The role of C3 in EM lesion development was demonstrated in a murine model, in which wild-type (WT) mice showed a higher incidence of cyst formation than C3 knockout (KO) mice; furthermore, peritoneal washings from WT mice with EM contained a greater number of degranulated mast cells than those from C3 KO mice. The same study further showed that C3a, which is known to affect mast cell function via C3aR signaling (102), promoted mast cell recruitment and activation, generating an auto-amplifying inflammatory loop that stimulates lesion engraftment (69). These findings underscore the relevance of C3 in EM pathogenesis, suggesting the potential therapeutic application of anti-C3 antibodies and C3a/C3aR axis targeting.
The endometriotic microenvironment itself may also favour alternative pathway activation. Indeed, heme, released from hemoglobin during hemolysis, has been identified as an activator of the alternative pathway by supporting C3(H2O) generation (103). Its established role in EM progression may be linked to enhanced alternative complement pathway activation.
). Heme is present in endometriotic lesions as a result of cyclical bleeding and in the peritoneal microenvironment due to retrograde menstruation (In addition to the 35 articles analyzing C3 in EM, omics studies have also reported an increase in the alternative pathway-specific components FB, FD, and FP. Collectively, these observations indicate that the alternative pathway may play a pivotal role in the pathogenetic mechanisms underlying EM development.
4.3 Terminal pathway
Although evidence regarding the terminal pathway remains limited, current findings suggest a potentially intriguing role in EM pathogenesis. Among terminal pathway components, C7 has been identified as the most consistently upregulated complement-associated gene in ectopic lesions, despite the limited evidence of terminal pathway activation. The consistent identification of C7 in multi-omic studies, along with its synthesis by endometriotic cells, suggests that its function in the EM microenvironment may extend beyond serving merely as a structural component of the MAC. C7 may exert alternative, complement-independent or regulatory functions that require further investigation. In this regard, Toffoli et al. recently proposed that C7 could act as an inhibitor-like decoy (104), similar to the mechanism previously described by Bossi et al. in endothelial cells (105). The authors demonstrated membrane-associated C7 expression on endometriotic cells and provided evidence of local C7 production within the peritoneal cavity in a subset of patient PFs, suggesting that lesion-derived C7 may actively contribute to shaping the inflammatory microenvironment in EM (104).
Interestingly, one study investigating EM-associated ovarian cancer reported increased C7 levels upon KRAS activation, while C7 knockdown inhibited ovarian cell proliferation (106). One possible mechanism inolves the C5b9, which, when formed at sublytic levels, can promote cell proliferation and inhibit apoptosis (107). Given the similarities between EM and cancer in several cellular processes, these mechanisms may also be relevant to endometriotic lesion progression.
). Previous studies have suggested that increased expression of C7 may promote cancer development (Although only a few studies identified C9 as a promising complement-associated biomarker in EM, those available include large case series. Interestingly, an important investigation analyzing serum proteome alterations in EM patients compared to healthy controls, involving 547 EM patients and 79 control women, demonstrated that not only C3, FB, CLU and FH but also C9 were differentially present in EM sera (46). Moreover, a recent large-scale study identified a panel of ten protein biomarkers across three statistical models based on proteomic evaluations, which added significant value to clinical factors; complement component C9 demonstrated a positive association with EM. The model accurately distinguished symptomatic controls from early-stage EM in the remaining dataset (AUCs ≥0.85 for stage I to III EM) (90).
Evidence regarding activation of the terminal pathway remains inconclusive. Kabut and colleagues demonstrated increased sC5b9 levels in a cohort of 80 cases compared to 30 controls in both sera and PFs (50). In contrast, Riley et al. did not observe significant differences in sC5b9 levels, although this study involved a smaller cohort (91).
4.4 Complement regulators
One of the most interesting findings from this review is the concurrent dysregulation of complement components and their regulators in endometriotic lesions, which may reflect a local feedback mechanism that limits excessive complement-mediated tissue damage. Alternatively, increased expression of complement regulators may contribute to endometriotic cells’ ability of to evade complement-mediated immune clearance. However, the gene regulation systems governing complement component and regulator genes remain insufficiently characterized.
Among complement regulators, FH is the most extensively studied protein in EM. This inhibitor exhibits multiple roles both within and beyond complement activation. FH serves as the primary soluble negative regulator of the complement alternative pathway and is essential for inhibiting complement amplification on target cells and host tissues. It protects tissues by attenuating C3b on self-surfaces and limiting MAC formation. FH regulates C3 cleavage through its decay-accelerating and cofactor activities for FI, thereby mitigating complement-mediated tissue damage. Additionally, FH binds to ligands on apoptotic and necrotic cells, such as DNA and histones, to reduce pro-inflammatory effects and prevent the release of autoantigens that could trigger autoimmunity (108). A non-canonical intracellular function of FH that may be relevant also in EM has recently been described in tumor progression. Roumenina’s research group demonstrated that FH can promote cell proliferation through cell cycle regulation. Specifically, IL-6-induced FH overexpression may interfere with p53 binding to E2Fs during the G1 phase, thus preventing p53 transactivation and cell death (109). Furthermore, FH binds directly to multiple components of the hemostatic system, including thrombin, fibrinogen/fibrin, FXII, FXI, FXIIIa, von Willebrand factor, platelets, and thrombomodulin (110). These interactions suggest that its synthesis by EM lesions may be involved in modulating local hemostatic processes, particularly in ovarian chocolate cysts.
Other complement regulators have also been investigated in EM. For example, C1INH levels were found to be higher in PFs of patients than in controls, suggesting a possible abnormal complement regulation in the peritoneal cavity at the level of the classical and lectin pathways (111).
). C1INH inhibits the classical complement pathway (C1r and C1s), the lectin pathway (MASP1 and MASP2), and also contributes to the regulation of the alternative pathway. In addition, C1-INH can also control serine proteases involved in coagulation and kinin systems, including Factors XIIa and XIa, kallikrein, plasmin, and tissue plasminogen activator (4.5 Strengths and limitations of the systematic literature review
To our knowledge, this is the first systematic literature review focusing on the available evidence regarding complement components as potential biomarkers in EM. A fundamental strength of the current study lies in the comprehensive search strategy, covering the three major biomedical databases (PubMed, Scopus, and Embase) in accordance with the PRISMA guidelines, which allowed a ready-to-use coverage of the studies investigating complement components in EM across different biological matrices (i.e., serum, peritoneal fluid, and ectopic/eutopic tissue) and employing different experimental approaches. This approach may help identify the most promising candidates for future validation as diagnostic biomarkers in EM.
However, some methodological limitations should be acknowledged. First, despite the comprehensive search, some relevant studies may not have been captured, particularly those published as conference proceedings or not indexed in the selected databases. In addition, we included only research papers reporting measurable outcomes of differential expression of complement components, which may have led to the exclusion of potentially relevant studies. We included only publications in English, which may introduce language- and country-specific biases, potentially limiting the generalizability of our findings. Lastly, heterogeneity across the included studies in terms of study design, sample type, analytical methods, and patient characteristics may affect the comparability of results and hinder the ability to draw definitive conclusions for some components.
5 Conclusions
Separate sections were dedicated to C3, C7, and FH because these molecules emerged as the most extensively investigated complement components in EM and showed the most consistent alterations across independent studies. Collectively, these findings support C3, C7, and FH as promising candidates for a complement-based biomarker panel for EM. While current evidence mainly derives from tissue and blood analysis, future studies should explore their potential as non-invasive urinary biomarkers, as previously proposed for complement biomarkers in preeclampsia (112).
). Additionally, their pronounced differential expression between endometriotic and healthy tissues raises the possibility of exploiting these molecules as targets for intraoperative molecular imaging probes to assist surgeons in removing all pathological tissue during lesion excision, thereby reducing the risk of disease recurrence (Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
Author contributions
AB: Conceptualization, Data curation, Methodology, Writing – original draft, Writing – review & editing. PT: Writing – original draft. GZ: Writing – review & editing. GDL: Writing – review & editing. GR: Funding acquisition, Supervision, Writing – review & editing. RB: Methodology, Supervision, Writing – review & editing. CA: Conceptualization, Data curation, Funding acquisition, Methodology, Supervision, Writing – original draft, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Italian Ministry of Health, through the contribution given to the Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste -Italy.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors RB, CA, GR declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2026.1991241/full#supplementary-material